Rapidly innovating: Drug formulations, diagnostics and neurologic drugs

Get our press releases & latest news first

Stay up to date. Find out about our latest research, products, exclusive partnerships and more.

We’re a leading bioscience company

With a global team and strategic collaborations, XPhyto is striving to make a real impact on medical innovation

XPhyto brings together cutting-edge companies and top researchers from around the world to innovate, accelerate and commercialize disruptive technology, from drug delivery formulations to diagnostics.

Learn More About Us

Innovative and Cutting-Edge Solutions

Our main areas of focus include:

Precision transdermal and oral drug formulations

Point-of-care (POC) diagnostics including rapid infectious disease screening

Production, formulation and validation of new active pharmaceutical ingredients (APIs)

Drug Delivery

Innovative drug delivery methods such as transdermal patches and oral dissolvable films for efficient and affordable treatment of a host of neurological diseases.

Scientist looking in magnifying glass XPhyto

Point-of-Care Diagnostics

Development of effective, accessible rapid testing and biosensors for early detection and the potential for better treatment outcomes.

Psychedelics

Promising treatments for depression, anxiety, drug and alcohol addictions, and post-traumatic stress disorder (PTSD) that are effective, safe, non-toxic and non-addictive.

Rapid delivery; development and production of active pharmaceutical ingredients.

We’re working with world-class life science industry and academic leaders

See Our Companies See Our Partnerships

Innovation to Impact

Pandemic Management and Impacts on Mental Health & Addictions

Our research and innovation have the potential to impact lives around the world.

Learn more about how XPhyto products could change the lives of people suffering from conditions and how our new research may impact the state of our global community.

Learn About Our Impact

Featured News

Diagnostics, Press Releases

XPhyto’s acquisition target, 3a-diagnostics, reports breakthrough identification of COVID-19 biosensor candidates

Jul 28, 2021

First saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto’s oral dissolvable delivery platformBiosensor candidates are ready for optimization and performance assessmentDevelopment of...

Diagnostics, Press Releases

XPhyto signs transformative acquisition agreement with 3a-diagnostics, to enter hi-tech biosensor market and expand its diagnostic product portfolio

Jul 20, 2021

The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well as cost synergies and improved margins on its diagnostic products.The acquisition secures...

Diagnostics, Press Releases

XPhyto Supplies 10 Test Centers in Berlin with 25-minute COVID-19 PCR Test

Jun 30, 2021

XPhyto signs master supply agreement with operator of 10 COVID-19 test centersThe test will be offered to customers as a rapid PCR test with sample...

Invest in Xphyto two happy investors talking

Invest in XPhyto, invest in innovation

Learn more about XPhyto’s innovation to impact strategy and get access to XPhyto investor information.

CSE:XPHY FSE:4XT OTCQB:XPHYF

Investor Information Corporate Presentation

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.